Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) shares saw unusually-strong trading volume on Thursday after Piper Jaffray Companies raised their price target on the stock from $23.00 to $26.00. Piper Jaffray Companies currently has an overweight rating on the stock. Approximately 2,621,465 shares were traded during mid-day trading, an increase of 459% from the previous session’s volume of 468,681 shares.The stock last traded at $17.73 and had previously closed at $17.00.

VNDA has been the topic of a number of other reports. Zacks Investment Research lowered shares of Vanda Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research note on Tuesday, July 18th. Jefferies Group LLC restated a “buy” rating and issued a $21.00 price target on shares of Vanda Pharmaceuticals in a research report on Tuesday, August 29th. HC Wainwright set a $18.00 price target on shares of Vanda Pharmaceuticals and gave the stock a “buy” rating in a research report on Thursday, August 3rd. Oppenheimer Holdings, Inc. set a $21.00 price target on shares of Vanda Pharmaceuticals and gave the stock a “buy” rating in a research report on Thursday, August 3rd. Finally, BidaskClub upgraded shares of Vanda Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, August 22nd. One equities research analyst has rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus target price of $21.63.

Several institutional investors have recently modified their holdings of VNDA. Legal & General Group Plc boosted its position in shares of Vanda Pharmaceuticals by 37.4% during the 2nd quarter. Legal & General Group Plc now owns 11,105 shares of the biopharmaceutical company’s stock valued at $181,000 after acquiring an additional 3,022 shares in the last quarter. Virginia Retirement Systems ET AL bought a new position in Vanda Pharmaceuticals during the 1st quarter valued at about $193,000. Capital Fund Management S.A. bought a new position in Vanda Pharmaceuticals during the 1st quarter valued at about $195,000. Dynamic Technology Lab Private Ltd bought a new position in Vanda Pharmaceuticals during the 1st quarter valued at about $196,000. Finally, Kopp Investment Advisors LLC bought a new position in Vanda Pharmaceuticals during the 2nd quarter valued at about $196,000. Institutional investors and hedge funds own 86.49% of the company’s stock.

The stock’s 50-day moving average is $16.42 and its 200 day moving average is $15.18. The stock’s market capitalization is $825.39 million.

Vanda Pharmaceuticals (NASDAQ:VNDA) last released its quarterly earnings results on Wednesday, August 2nd. The biopharmaceutical company reported ($0.03) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.21) by $0.18. The business had revenue of $42.06 million for the quarter, compared to the consensus estimate of $40.31 million. Vanda Pharmaceuticals had a negative net margin of 6.54% and a negative return on equity of 7.85%. Vanda Pharmaceuticals’s revenue was up 16.7% compared to the same quarter last year. During the same period in the prior year, the company posted $0.01 earnings per share. On average, analysts predict that Vanda Pharmaceuticals Inc. will post ($0.44) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This news story was posted by Daily Political and is the property of of Daily Political. If you are accessing this news story on another website, it was stolen and republished in violation of U.S. & international copyright laws. The correct version of this news story can be read at https://www.dailypolitical.com/2017/09/15/vanda-pharmaceuticals-inc-vnda-sees-strong-trading-volume-after-analyst-upgrade.html.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to address unmet medical needs. Its product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051. It offers HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24).

Receive News & Ratings for Vanda Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.